Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report. - Wikidata - awgldk - TriplyDB

Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.

Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.

http://www.wikidata.org/entity/Q35142182

about

Drug resistance to targeted therapies: déjà vu all over again Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups

P2860

Q38218657-1ED6C9BF-11FE-464F-9A35-00BB7629EA9E Q42346622-6182F319-8EC0-4A87-A392-40697C417AE9

P2860

Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: a preliminary report.

http://www.wikidata.org/entity/Q35142182

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@ast

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@en

type

label

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@ast

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@en

prefLabel

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@ast

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@en

P1433

Q35142182-2881F4EC-090F-48AB-8E55-CB5BF8D523F2

P1476

Q35142182-67588F20-5EA4-42C7-85DE-4E75AC6E38D7

P2093

Q35142182-02C281D7-1217-4EB5-B083-C5573BB56038

Q35142182-03FF62CD-3E94-4049-9779-7C6ADB77CC9A

Q35142182-1165AD02-D3E4-4278-B81D-C4583B41A8C8

Q35142182-18FE964A-8E37-48B7-904A-4E3ECE1B3D0B

Q35142182-3DBF9927-97C8-4609-B2FD-9376427C9141

Q35142182-4AD09FDB-1D93-4C8B-AE9D-FE9A577E9075

Q35142182-82926624-1F1F-4554-A288-A975E64A0AD0

Q35142182-8ED1E3E0-7736-48ED-B846-96127A561B23

Q35142182-AAFF5C9A-4DEF-4964-9FA5-DC94CE2727C2

Q35142182-DBBD5DC8-3E25-44F9-93B5-72233C129D40

P2860

Q35142182-2B4F5236-0A94-4D29-A975-507228DA2958

Q35142182-2EFED8B2-7FCB-405D-B7F3-7C69EB7D59DE

Q35142182-57253BE3-40C5-4AC5-A897-942497D7B0D4

Q35142182-62609995-E6EB-4299-AE8C-E2F738B8C248

Q35142182-6441911F-1F3D-48A0-ABAA-9395113595F9

Q35142182-7ACBB852-2C4C-4D93-A6A2-EA2EA9B8410E

Q35142182-7C9CF8A2-D0D7-4591-B516-3C178C2E1AC5

Q35142182-87AA753F-D446-49C5-9F66-EF8F94785366

Q35142182-A0F1D627-8F17-42F1-A061-0EBA6DCBD2CF

Q35142182-B6C48157-06BA-4956-8874-878C3E8A85F2

P304

Q35142182-4EA04571-748D-4E1A-BBBE-7030BA0A3A37

P31

Q35142182-F4D698C6-EE1E-454A-A9E4-6DBBA6EA9559

P356

Q35142182-42128BD4-61E0-4CBA-9189-85833AFBEE5A

P433

Q35142182-2E8B90A6-D7FF-4E83-9F8D-5B513E48DAE8

P478

Q35142182-8D9FAEE7-8DFC-4789-8CDE-9133D72B58B1

P577

Q35142182-9532B225-B20C-4D6A-92F1-31E615841BC6

P5875

Q35142182-E4F921E7-07AC-49F8-9C2E-E6C37C05B46B

P698

Q35142182-96189517-2A05-4BCD-BB5E-02552B744D83

P932

Q35142182-6BCA7FDC-75F8-41F6-9221-A8D990D4E758

P356

JBC.2011.14.2.135

P1433

Journal of breast cancer

P1476

Efficacy of fulvestrant in hea ...... cancer: a preliminary report.

@en

P2093

Byung-Ho Son

http://www.w3.org/2001/XMLSchema#string

Changhoon Yoo

http://www.w3.org/2001/XMLSchema#string

Gyungyub Gong

http://www.w3.org/2001/XMLSchema#string

Hak-Hee Kim

http://www.w3.org/2001/XMLSchema#string

Hee-Jung Kim

http://www.w3.org/2001/XMLSchema#string

Jin-Hee Ahn

http://www.w3.org/2001/XMLSchema#string

Kyung Hae Jung

http://www.w3.org/2001/XMLSchema#string

Sei-Hyun Ahn

http://www.w3.org/2001/XMLSchema#string

Sung-Bae Kim

http://www.w3.org/2001/XMLSchema#string

Yongchel Ahn

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

Fulvestrant (Faslodex) -- how to make a good drug better.

Early- and late-onset breast cancer types among women in the United States and Japan.

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

P304

135-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4048/JBC.2011.14.2.135

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51576827

http://www.w3.org/2001/XMLSchema#string

P698

21847409

http://www.w3.org/2001/XMLSchema#string

P932

3148533

http://www.w3.org/2001/XMLSchema#string